Associated Papers
Modeling (not so) rare developmental disorders associated with mutations in the protein-tyrosine phosphatase SHP2.
Solman M et al.
Frontiers in Cell and Developmental Biology, 2022
Targeting SHP-1-STAT3 signaling: A promising therapeutic approach for the treatment of cholangiocarcinoma.
Hu MH et al.
Oncotarget, 2017
SHP-1 is a target of regorafenib in colorectal cancer.
Fan LC et al.
Oncotarget, 2014
Discovery of novel Src homology region 2 domain-containing phosphatase 1 agonists from sorafenib for the treatment of hepatocellular carcinoma.
Tai WT et al.
Hepatology (baltimore, Md.), 2014
Noonan syndrome-associated SHP-2/Ptpn11 mutants enhance SIRPalpha and PZR tyrosyl phosphorylation and promote adhesion-mediated ERK activation.
Eminaga S et al.
The Journal of Biological Chemistry, 2008
Abstracts of the 45th Annual Meeting of the Japanese Society for Neurochemistry. Sapporo, Japan. July 17-19, 2002.
Unknown Author
Neurochemical Research, 2003
Shp-2 positively regulates brain-derived neurotrophic factor-promoted survival of cultured ventral mesencephalic dopaminergic neurons through a brain immunoglobulin-like molecule with tyrosine-based activation motifs/Shp substrate-1.
Takai S et al.
Journal of Neurochemistry, 2002
Select a paper to view details